Document is current
Any future updates will be listed below
-
Authors
Pham, Tammy B.
Boussaty, Ely Cheikh
Currais, Antonio
Maher, Pamela
Schubert, David R.
Manor, Uri
Friedman, Rick A.
-
Funding
Funding for this research was provided by:
Shiley-Marcos Alzheimer's Disease Research Center (to Currais)
National Institutes of Health (R01AG067331)
National Institutes of Health (AI104034)
National Institutes of Health (AI104034)
National Institutes of Health (R01DC018566)
National Institute on Deafness and Other Communication Disorders (R21 DC018237)
National Institute on Deafness and Other Communication Disorders (R21 DC018237)
National Cancer Institute (CA014195)
Waitt Foundation (to Manor)
CZI Imaging Scientist Award (to Manor)
- License Information
-
More Information
Article History
Received: 12 July 2022
Accepted: 17 April 2023
First Online: 25 April 2023
Declarations
:
: The SAMP8 line was originally acquired from Harlan Laboratories (U.K) and subsequently bred and housed at the Salk Institute in accordance with the US Public Health Service Guide for Care and Use of Laboratory Animals and protocols approved by The Institutional Care and Use Committee (IACUC) at the Salk Institute. ABR testing and subsequent cochlear harvesting were performed on the SAMP8 mice in accordance with protocols approved by the IACUC at the University of California, San Diego.
: The Salk Institute holds the patent for CMS121 (US9744164). Otherwise, the other authors declare no competing financial interests.
